GET DAILY SIGNALSIDEAYA Biosciences (IDYA) Posts Q3 2026 Results With NDA Filing and Extended Cash Runway
Key Takeaways
- IDEAYA Biosciences reported a third quarter 2026 net loss of $125.7 million, or $1.22 per share, widening from a net loss of $112.5 million in the second quarter of 2026.
- Collaboration revenue rose to $10.2 million, up from $8.9 million in the prior quarter, exceeding the consensus estimate of roughly $7.6 million.
- The loss per share of $1.22 came in slightly below the consensus estimate of approximately $1.16, while revenue beat expectations.
- Research and development (R&D) expenses climbed to $121.6 million, reflecting the company's advancing clinical pipeline.
- IDEAYA completed its first NDA (New Drug Application) filing for darovasertib in metastatic uveal melanoma, a key commercial milestone.
- The company held approximately $1.15 billion in cash, cash equivalents, and marketable securities, with its cash runway guidance into 2030 unchanged.
Earnings Context and Why It Matters
As a clinical-stage precision medicine oncology company, IDYA does not yet generate product sales, so its quarterly results are shaped less by traditional revenue than by pipeline execution, partnership economics, and disciplined cash management. The third quarter of 2026 stands out because it included the company's first NDA filing for darovasertib, its lead program in metastatic uveal melanoma, a rare eye cancer. Investors are watching whether the company can convert clinical data into regulatory progress while keeping spending on track. A widening net loss driven by rising R&D and general and administrative (G&A) costs is expected for a company advancing multiple programs, making the cash runway and near-term clinical catalysts the true focal points of this report. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, IDEAYA reported collaboration revenue of $10.2 million, up from $8.9 million in the second quarter of 2026, and above the consensus estimate of roughly $7.6 million. Revenue is recognized over time under the Servier exclusive license agreement for darovasertib, tied to research and development services.
Net loss for the quarter was $125.7 million, or $1.22 per share, compared with a net loss of $112.5 million in the prior quarter. The per-share loss of $1.22 came in modestly below the consensus estimate of approximately $1.16. R&D expenses rose to $121.6 million from $108.7 million sequentially, while G&A expenses increased to $26.3 million from $22.5 million.
The company ended the quarter with approximately $1.15 billion in cash, cash equivalents, and marketable securities, down from $1.24 billion as of June 30, 2026, driven primarily by cash used in operations. Management reiterated that its cash runway extends into 2030 under the current operating plan.
Market Reaction and Investor Sentiment
IDEAYA shares have declined roughly 8% since the start of 2026, underperforming the broader market, even as the company advanced its pipeline and completed its first NDA filing. The third quarter results highlighted a familiar dynamic for biotech investors: the earnings miss versus consensus was driven by rising clinical spending, while the revenue beat and the darovasertib regulatory milestone anchored the longer-term thesis. Sentiment around the stock remains tied to the company's ability to execute on clinical and regulatory catalysts rather than near-term profitability. With a consensus price target well above recent trading levels, analyst expectations remain constructive, but investors are closely watching whether upcoming data readouts support that view.
Forward Outlook and Key Factors to Monitor
Looking ahead, IDEAYA's story centers on a series of defined catalysts rather than quarterly earnings. The darovasertib NDA in metastatic uveal melanoma is the flagship near-term milestone, and investors will monitor regulatory interactions and any updates on potential approval timing.
On the clinical side, the company plans to host an R&D Day on November 16, 2026, where it will present new preclinical data on its MTAP/CDKN2A franchise in RAS-mutant cancers. This event is expected to provide scientific rationale for the clinical collaborations IDEAYA recently established with Roche and Genentech.
Several additional programs are advancing, including IDE849, a DLL3-directed TOP1i antibody-drug conjugate (ADC), in small-cell lung cancer and neuroendocrine tumors, as well as IDE892 and IDE397 in MTAP-deleted cancers. Investors should also watch expense trends, as R&D costs are likely to remain elevated with multiple trials enrolling simultaneously.
With approximately $1.15 billion in cash and a runway into 2030, IDEAYA has meaningful financial flexibility to fund its pipeline. The key question is whether the company can translate its expanding clinical portfolio into regulatory and commercial progress over the next several quarters. From what I see, this financial cushion provides important optionality.
Integrating AI Tools Into Biotech Research
In my analysis of names like IDYA, I often turn to Tickeron’s AI Screener to quickly filter biotech peers by technical patterns, fundamentals, and AI-driven signals. It helps surface comparable setups across the sector without manual effort, which is especially useful when tracking clinical-stage companies with similar pipelines and cash positions. This approach has become a regular part of how I evaluate relative strength and potential catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IDYA in downward trend: price dove below 50-day moving average on October 06, 2026
IDYA moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend. In 30 of 36 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IDYA as a result. In 84 of 109 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for IDYA turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 33 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
The 10-day moving average for IDYA crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
The Aroon Indicator for IDYA entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IDYA's RSI Oscillator exited the oversold zone, 30 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDYA advanced for three days, in 218 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
IDYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.521) is normal, around the industry mean (3.104). P/E Ratio (-16.318) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (14.409) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. IDYA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an oncology-focused precision medicine company committed to the discovery and development of targeted cancer therapeutics for patient populations selected using molecular diagnostics.
Industry Biotechnology
Advertisement